Frequently Asked Questions:
TheraPsil is a coalition of healthcare practitioners, patients and advocates dedicated to fighting for the rights of Canadians in medical need to have legal access to psilocybin therapy.
Our main focus at this time is to support patients who have, or have had a life-threatening diagnosis (ie. current cancer patient or cancer survivor) to access legal, medically-supervised psilocybin-assisted psychotherapy.
Although we hope to eventually facilitate access to psilocybin-assisted psychotherapy to all Canadians in medical need, we have decided to currently limit our support to those with end-of-life and illness-related distress, as this treatment has the most rigorous scientific evidence demonstrating therapeutic efficacy and safety. We also limit ourselves to helping only those facing end-of-life and illness-related distress at this time as we are a small non-profit with limited capacity. We must ensure we only expand our services in accordance with our means and ability to provide safe and equitable care and ensure a high standard of support is provided to each patient.
The TheraPsil coalition is made up of healthcare practitioners (including doctors, therapists, and nurses), researchers, policymakers, lawyers, advocates, and support staff. To learn more about the TheraPsil team, please click here.
Currently, TheraPsil facilitates two primary functions:
- Supporting qualified Canadians in navigating government processes to gain legal access to psilocybin-assisted psychotherapy. This may be through navigating the Special Access Program (SAP) or by requesting an exemption to section 56(1) of the Controlled Drugs and Substances Act.
- Connecting patients with trained and qualified healthcare practitioners who can support and facilitate their psilocybin-assisted psychotherapy.
In addition to supporting patients, and facilitating compassionate access to psilocybin- assisted psychotherapy, our mission includes public education, training for healthcare practitioners and therapists, and facilitating research.
- We do not advocate for the illegal use or possession of psilocybin.
- We do not help patients find a source of psilocybin containing mushrooms or advise on source options.
- We do not encourage or advocate for self-medicating (i.e taking psilocybin without medical or therapeutic. protocols), however, we may support patients who have self-medicated with psilocybin in the past and are now seeking legal access, and professional treatment.
- At the present moment, we do not treat patients, and we are not a clinic, however, we can help connect patients with qualified healthcare practitioners to facilitate treatment.
No, at this time TheraPsil does not provide treatment to patients; we facilitate two primary functions:
- Supporting qualified Canadians in navigating government processes to gain legal access to psilocybin-assisted psychotherapy. This may be through navigating the Special Access Program (SAP) or by requesting an exemption to section 56(1) of the Controlled Drugs and Substances Act.
- Connecting patients with trained and qualified Healthcare Practitioners, working in their own private practice or clinic, who can support and facilitate psilocybin-assisted psychotherapy.
As of March 2021, TheraPsil has created and launched a psilocybin-assisted therapy training program for qualified Health Care Practitioners. TheraPsil has and continues to develop a pool of suitably trained and trusted TheraPsil Clinical Associates to whom we can refer patients. These clinician are often Therapists, Nurses, Socialworkers, Medical Doctors, Psychologists, etc.
Part of the benefit of a patient connecting to a TheraPsil Practitioner Associate is the guarantee that the practitioner is a part of a regulatory body, with a code of practice and ethics. They will have completed TheraPsil's training and will follow TheraPsil’s structured clinical protocol, including preparatory session, 2 sitters on the session day, integration, etc. With the practitioners being part of a regulatory body as well as associated with TheraPsil, it adds a level of safety.
To learn more about our training program visit our Training Webpage here.
About Psilocybin & Psilocybin-assisted Psychotherapy
Psilocybin is a compound found in many species of mushrooms that creates psychoactive and psychedelic effects, which may include alterations in sensation, cognition, and emotion. Psilocybin can be synthesized to better ensure the purity, potency, and accuracy of doses. Researchers use this synthetic form in their clinical trials. Psilocybin mushrooms may be more commonly referred to as 'magic mushrooms' or 'shrooms'.
No. TheraPsil does not, and legally cannot help patients or individuals procure ‘magic mushrooms’ or psilocybin in any form. Patients whose prescriber successfully receives special access to psilocybin on their behalf through the Special Access Program (SAP) may then be provided synthetic or natural psilocybin psilocybin directly from a regulated producer. At this time, we can only support patients to apply for section 56 exemptions who have their own source or means of procuring this fungus.
Psilocybin-assisted psychotherapy refers to the professionally guided use of psilocybin in combination with psychotherapy and differs greatly from the recreational use of psychedelics. Psilocybin-assisted psychotherapy involves a rigorous and clinically tested treatment protocol that encompasses careful medical oversight of the treatment session, as well as pre-and post-psychotherapy sessions that help prepare an individual for lasting healing.
The psychedelic psychotherapy process can be divided into three aspects; preparation, the treatment day, and integration.
To prepare, each patient is brought through a medical screening to ensure there are no medical contraindications and that psilocybin-assisted psychotherapy is the best option for them.
Once medical sign off is given, the patient will take part in at least three preparatory psychotherapy sessions. These preparatory sessions are opportunities for the patient to build trusting relationships with their therapy team, investigate what might come up for them during their treatment day, build on an intention or goal and plan logistics for the treatment day. It is important to note that even if a patient has been granted legal access to psilocybin, this does not guarantee the treatment day will occur, as the therapist and the patient together must determine that the patient is fully ready and safe to have a psilocybin experience.
After the preparatory sessions are completed and the therapy team feels the patient is ready, the treatment session takes place. On the treatment day, the patient ingests psilocybin with the constant supervision and support of two trained psychotherapy sitters. The location of treatment varies - sometimes this can take place in a therapist's office, the patient’s own home or a medical setting depending on the needs of the patient. The patient often lays on a couch, wearing eye shades and headphones, listening to a curated playlist of music. The patient is encouraged to “trust, let go, and be open” and focus their attention on their inner experiences throughout the session. At any time throughout the session, the patient can choose to do things such as remove the eye shades, change positions, or speak with the practitioners if they feel called to do so. The practitioner will oblige to the patient’s wishes, but will likely continue to encourage the patient to go inward to experience the journey of the psilocybin therapy throughout the session. The psilocybin treatment day begins and ends gradually, with a slow and supported shift out of and back into normal consciousness.
After the treatment day the patient attends approximately three integration sessions, with the first often on the day following the medicine session. These sessions are all about supporting the patient in finding some understanding and meaning around their medicine journey, and assisting them to integrate the experiences from the medicine day into their lives. Integrating the psychedelic experience into one's life is often the most impactful part of the psychedelic psychotherapy process. Along with the structured integration sessions provided, other examples of integration may be journaling one's thoughts, sharing insights with social supports or noticing shifts in one's views or habitual patterns. Integration is an ongoing process that continues into the future of one's life post treatment.
Research shows that psilocybin can have profoundly positive effects on people facing the end of life. One dose of psilocybin, accompanied by psychotherapy, can help reduce the depression, anxiety, and hopelessness that is often associated with the end-of-life experience. Psilocybin itself can induce spiritual or mystical states, feelings of unity, a profound sense of love and acceptance for all that is. This treatment can increase a sense of spiritual connectedness and meaning in life, while at the same time reducing a desire to hasten death and the existential anxiety that is associated with facing the end of life.
Yes! All around the world groundbreaking research has been and is being done regarding psilocybin-therapy. This research has shown the effectiveness of psilocybin in combination with skilled psychotherapy to reduce depression, anxiety, and end-of-life distress for those living with a terminal illness, in palliative care or who are experiencing distress as a result of a life-threatening illness.
Foundational studies on psilocybin-assisted psychotherapy can be found at the following links:
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial
- Individual Experiences in Four Cancer Patients Following Psilocybin-Assisted Psychotherapy
We have amalgamated a bibliography of research, here.
TheraPsil is also contributing to current and future psilocybin research. Observational research studies have been designed in collaboration with researchers from McGill University, Northern Ontario School of Medicine, and the world’s first Psychedelic Research Centre at Imperial College, London. All eligible patients granted legal access to psilocybin therapy have the opportunity to take part in this research initiative. Find out more about past and present psilocybin research here.
Psilocybin-assisted psychotherapy is an active process that a patient must engage in, with intention. Like many things in life, you often get out what you put in. The more dedicated one is to their own preparation, experience and integration, the more likely positive results will incur and be sustained. No two psilocybin experiences are the same, and some patients may not experience the positive effects named above. For some, the experience is not life-changing. It is important to go into the psilocybin session with direction but without strong expectations, being open to whatever you experience.
As with all treatments, there are contraindications and risks. However, the medical literature suggests that psilocybin-assisted therapy can be a safe and effective treatment option for end-of-life distress, in comparison to other treatments. The safety profile of psilocybin-assisted psychotherapy is different from the recreational use of psychedelics as the treatment setting is carefully prepared, the psychotherapist works to prepare the patient, and monitor the session. Research also shows that psilocybin is not addictive. Rather, psilocybin is actually anti-addictive, meaning that some individuals who consume psilocybin tend to reduce their consumption of other substances.
There are physical and psychological reasons in which psilocybin therapy may not be a safe option for some people. TheraPsil ensures a healthcare prescriber oversees a medical screening before psilocybin therapy is pursued to ensure all contraindications are assessed.
While under the influence of psilocybin, an individual's consciousness is heavily altered. This can be a very vulnerable situation. This is why a solid foundation of trust between the therapist and the patient is of utmost importance. Patient’s supported by TheraPsil Practitioner Associates for their psilocybin treatment are provided many preparatory sessions to ensure trust and safety is established before the potential treatment day occurs.
You may have heard about psychedelics and the ominous “bad trip”. These so-called “bad trips” are often had when the proper support and planning is not in place surrounding an altered state, such as when one is at a social gathering or while using a psychedelic alone. A psilocybin experience can be physically and emotionally uncomfortable at times. Some patients report bouts of nausea, perspiration, tremors, fear, and anxiety when working through challenging experiences. Although it is important to note that within the supportive framework of psychotherapy, with two trusted and trained practitioners holding steady support for an individual, surrendering to and working through challenging experiences is often considered incredibly valuable and at times transformative.
Accessing Legal Psilocybin Therapy
TheraPsil supports Canadians experiencing end-of-life distress / existential distress as a result of a past or present terminal or life-threatening diagnosis, to exercise their charter right to seek compassionate treatment using psilocybin.
We do this by providing clear guidelines on our website for patients and their supporting practitioners to understand the ways in which they can approach pursuing each possible current avenue to access legal psilocybin-assisted psychotherapy.
TheraPsil provides a medical screening document called our Patient Inclusion Criteria (PIC) form that prescribing practitioners can utilize to ensure there are no medical contraindications and help guide them to decide if psilocybin is the right for you. TheraPsil also provides additional education and support to prescribing practitioners to help them complete these patient assessments.
TheraPsil can provide support to your prescribing healthcare practitioner if they are unfamiliar with the Special Access Program (SAP) and need support completing the paperwork.
If a practitioner successfully gains access to psilocybin for their patient through an SAP request, TheraPsil will refer patients to trained and qualified therapists working within their own private practices who can facilitate psilocybin-assisted psychotherapy.
If a patient does not have access to a clinical trial and an SAP request is submitted and denied or not suitable, TheraPsil can then guide that patient to apply to the Minister of Health for a section 56 exemption.
If a patient is successfully granted a section 56 exemption by the Minister of Health, TheraPsil will refer patients to trained and qualified therapists working within their own private practices who can facilitate psilocybin-assisted psychotherapy.
Direct your prescribing healthcare practitioner to visit our Support your patients page for instructions on how they can support you in pursuing access to legal psilocybin-assisted psychotherapy.
As of January 2020, TheraPsil supports Canadians who meet the following criteria.
- You are a resident of Canada over 19 years of age, with existential distress as a result of a past or present terminal or life-threatening diagnosis,
- As a result of your past or current diagnosis you experience psychological distress (anxiety/depression/demoralization/ hopelessness),
- Your emotional distress has not successfully responded to other treatments,
- You are interested in trying psilocybin-assisted therapy,
- You have a prescribing health care provider who will support you in applying for legal access to psilocybin-assisted therapy.
Although we hope to eventually provide support in accessing psilocybin-assisted psychotherapy to all Canadians in medical need, we have decided to currently limit our treatment scope to end-of-life and illness-related distress, as this treatment has the most rigorous scientific evidence demonstrating therapeutic efficacy and safety. We also limit ourselves to helping only those facing end-of-life and illness-related distress at this time as we are a small non-profit with limited capacity. We must ensure we only expand our services in accordance with our means and ability to provide safe and equitable care and ensure a high standard of support is provided to each patient.
If you, or someone you know, are interested in legal access to psilocybin-assisted psychotherapy, you can find out more about your options here.
TheraPsil’s team cannot guarantee the success of any request to Health Canada for legal access to psilocybin for us in conjunction with psychotherapy,
Unfortunately, no. We can only help individuals who currently hold permanent residency in Canada and have a provincial Health Card Number.
We are a non-profit patient advocacy organization. We guide individuals living in Canada, who meet our inclusion criteria, to apply for legal access to psilocybin via the Special Access Program (SAP) or for a section 56 exemption from the Controlled Drugs and Substances Act (CDSA). When SAP applications or section 56 exemptions are approved, we refer patients to trained practitioners to provide this legal treatment.
The Controlled Drugs and Substances Act (CDSA) is Canada's federal drug control statute that prohibits activities related to controlled substances and precursor chemicals.
Section 56 of the CDSA states that:
“An exemption may be granted to allow a controlled substance or precursor to be used for specific scientific or medical purposes, or when it is determined to be in the public interest.”
This permits certain activities with controlled substances that would otherwise be illegal. Health Canada reviews each request on a case-by-case basis and considers all relevant information before making a decision.
Section 56.1 of the CDSA goes on to say that:
“The Minister (of Health) may grant an exemption if it’s believed to be necessary for medical or scientific purposes, or in public interest.”
This means that only the Minister has the authority under Section 56 to approve exemptions for controlled substances in Canada. And it further states that the Minister's decisions must be made public and that a reason must be provided for any refusals.
Section 56 exemptions are flawed for several reasons - most notably because wait times can be up to 300 days and patients have to source their own psilocybin from the illegal market.
The ‘Special Access Program’ (SAP) allows healthcare practitioners to request limited access for their patients to drugs that are not yet authorized for sale in Canada. For several years, Canadian healthcare providers have relied on this SAP to access otherwise unavailable drugs - particularly when traditional paths fail to yield positive outcomes. For example, the SAP might grant access to a not-yet-approved chemotherapy drug for a patient with a rare tumor or a new antiviral for a patient with long-standing, treatment-resistant HIV.
Prescribing healthcare professionals (e.g doctors or nurse practitioners) must request access to a drug through the SAP on behalf of a specific patient. The SAP request form is 8 pages long and requests practitioner information, drug and manufacturer information, patient information, and clinical rationale (including research) among other details. This request is approved on a patient-by-patient basis examining the individual needs of that patient to determine whether said patient could benefit from a drug that is not yet legally available in Canada. Currently, the SAP and Clinical Trials are Health Canada's preferred access route.
Typically, restricted drugs are not considered drugs with approved medical uses and are therefore excluded from the SAP. However, the efficacy and safety of certain restricted drugs for treatment of mental and physical illnesses have become more established in the present day.
Therefore, on January 5th, 2022, Health Canada amended the Food and Drug Regulations and the Narcotic Control Regulations (part of the CDSA) to allow psychedelic drugs (including psilocybin) to be included in the SAP.
Section 56 exemptions are now a secondary pathway to access, and only pursued if an SAP request has been denied.
The SAP is intended for patients who:
- Have a serious or life-threatening condition.
- Have not responded to conventional treatments (or, have no suitable treatment options for their condition).
Factors taken into account when determining eligibility include:
- The need for hospitalization or in-patient care
- The risk of adverse pregnancy outcomes
- The risk of persistent disability in absence of treatment
- The prognosis of the condition
Your request must be for treating a patient where conventional treatments:
- Have failed
- Are unsuitable
- Are not available in Canada
TheraPsil is a non-profit advocacy group and accepts donations from a variety of sources including for-profit organizations in the psychedelic and bio-science space, and private individuals through crowd-funding.
As a small non-profit we rely on donations to operate. We cannot continue to support Canadians in accessing legal psilocybin now or continue to advocate for the enactment of medical psilocybin regulations in the future, without support from people like you!
If you are supportive of the work our team is doing and want to see psilocybin legalized in Canada, please consider donating. Even small donations help those in need of psilocybin therapy in Canada be able to continue to receive our support.
You may have read press releases that mention an organization or company that has ‘sponsored’ or ‘supported’ TheraPsil. This simply means that this organization has generously donated to TheraPsil to support our work and mission. This support allows us to continue and accelerate our work, and maintain the day-to-day operations of TheraPsil.
Our donors have no impact or influence on TheraPsil’s strategy or motivations. Our agreements with these donors have and always will be ‘no strings attached. We are deeply committed to ethical and integrity-driven advocacy work that puts patients first - always. We appreciate the donations we have received and have never allowed financial support to sway or impact our clear mission and values.
TheraPsil Needs Your Support
To learn more about our advocacy efforts and how you can take action with us visit our Take Action webpage here.
Follow us on social media on facebook, instagram, twitter, and youtube. Share our messages, tagging the Minister of Health, Jean-Yves Duclos, and your MP so we can continue to get the message out to these individuals.
Register for our Webinar series where will amplify the voices of patients, healthcare professionals, and advocates, aiming to educate the public about the merits and limitations of psilocybin therapy, and advocating for regulatory change.
Sign up for a newsletter to have the inside scoop on what is happening as it happens.
Frequently Asked Training Questions:
Why Choose TheraPsil?
- Experience and Expertise: TheraPsil is home to pioneers in the psychedelic space who are paving the way for medical regulations for psilocybin access in Canada. TheraPsil supported the first patients and healthcare practitioners in Canada in accessing legal medical psilocybin. We aim to ensure that their graduates are fully prepared to guide clients through the therapeutic psilocybin experience including preparation, dosing, and integration.
- Ethical and Clinical Excellence: TheraPsil emphasises ethical, clinical, and academic excellence in the field of psychedelic treatment. We have a strong commitment to responsible, evidence-based practices.
- Small Cohort Sizes: Our cohorts are maxed at 12 participants, which allows for an intimate environment for trainees to create a safe container of trust while doing this work.
- In-person training: Our week-long intensive and experiential retreats are offered in-person to allow you to fully connect with fellow participants and trainers to get the most out of your training experience.
- Inclusivity: TheraPsil is a non-profit and we value diversity and encourage individuals from various backgrounds and underserved or marginalised communities to apply.
- Legal Support: TheraPsil is supporting our practitioners in court to ensure they can legally use psilocybin as part of our training programs. Central to our organisation is the belief that psilocybin holds tremendous potential for medical applications, and we are committed to ensuring that our practitioners can harness this powerful tool to provide the best care to their patients.
Community of Care and Practice: When you join TheraPsil, you join a network of 600+ healthcare professionals, patients, supporters, and advocates. Our training program offers networking opportunities with like-minded professionals in the field. Building a support network is crucial in the emerging field of psychedelic therapy.
Training Program Overview
TheraPsil's training program is designed to provide healthcare professionals with the knowledge and skills required to provide safe and effective psilocybin-assisted psychotherapy to Canadians in medical need. It covers a wide range of topics, including clinical assessment, ethical considerations, and the use of psilocybin in therapeutic settings; you can view the full curriculum above.
The program consists of in-person seminars, webinars, readings/videos, experiential training, and clinical supervision. The total program duration is 130 hours for MDs and RNs who do not have clinical experience and 140 hours for those with a clinical designation. The extra 10 hours of training is for supervision. TheraPsil provides online access to our training portal which holds all reading and audio materials with the exception of a few texts that need to be purchased by the participants.
The program is offered in a mixed model. The pre-readings, online webinars, and supervision can be done online. The week-long intensive must be attended in person (30 hours) as well as the experiential retreat (43 hours).
Eligible participants include individuals with medical degrees (MD, RN) or graduate degrees (MA, Ph.D.) in fields like psychology, counselling psychology, psychiatric social work, or psychiatric nursing. Applicants must be in current good standing as a professional member of a provincial clinical counselling or psychotherapy association having a Code of Ethics and a disciplinary body.
The above requirements may be relaxed to allow those in the process of completing a graduate clinical degree or professional registration, and credentialed spiritual/pastoral counsellors to attend a seminar in situations where a cohort is short one or two fully qualified clinical entrants prior to delivery.
Upon successfully completing the program, participants may be awarded certificates of completion, for Psychotherapy Associate, Medical Associate, Provisional Associate, or Co-Sitter status with TheraPsil. They will also be added to TheraPsil’s Practitioner Directory for patient referrals. For more information: please refer to the Training Pathways document and curriculum.
Accreditation & Associations
TheraPsil’s Fundamentals of Psilocybin-Assisted Psychotherapy Training program is approved for 140 hours of CE credits with the Canadian Psychological Association and the Canadian Counselling and Psychotherapy Association. We are note yet approved for CME credits for our Fundamentals Training Program, but MDs can apply for these with a Certificate of Completion from TheraPsil. TheraPsil’s Prescriber Training Program is approved for 6 CME credits through MainPro +.
In our discussions with colleges and associations, they have been supportive. Their response has been that as long as members are supporting clients legally with psilocybin through Canada’s SAP program, are working within their scope of work, have the necessary training, and are engaging in ongoing supervision they are supportive and consider this an alternative therapy.
Instructors & Facilitators
Our instructors and facilitators are experienced professionals and leaders in the field of psilocybin-assisted therapy. They hold relevant licenses and certifications and have practical experience in the use of psychedelics for therapeutic purposes. You can learn more about TheraPsil’s Training Team here. The specific trainer for each cohort is listed under ‘Upcoming Cohorts’ on our training page.
Logistics & Policies
- Early bird tuition: $3,650 + tax* (Sign up must be made three months prior to the cohort start date)
- One-Time Payment: $3,850 + tax
- 6-month Payment Plan: $4,150 + tax
Please note that TheraPsil reserves the right to change the tuition for all Training Programs without notification. To secure a spot, registration or a deposit must be paid within 7 days of acceptance. Failure to accept the spot within this period will result in forfeiture. For extension requests, please contact email@example.com.
Rooted in our identity as a non-profit organization, our team strives to maintain low-profit margins without compromising the value of our program. It's our belief that training should be accessible to as many people as possible within the scope of our organizational capacity, irrespective of their financial circumstances.
With this ethos in mind, if the cost of our training presents a genuine financial challenge for you and you are unable to otherwise participate, we urge you to apply for financial assistance. This will enable us to collaborate with you in exploring the available options for your participation in our program and community. You can apply for a bursary or financial aid here.
Participants will have access to administrative support staff as well as ongoing group or individual supervision throughout the program. This may include discussion forums, help desks, or direct contact with instructors or supervisors.
Yes, we encourage networking and collaboration among all TheraPsil stakeholders via our online Community of Care and Practice, Mighty Networks. We also host in-person Psychedelic Cafes across Canada on a regular basis.
- To hold your spot in the training without registering, a $1,000 deposit is required within 7 days of notification of acceptance into the program
- i.e. You cannot confirm the training dates and need 7 days to confirm your availability
- After the 7-day mark, spaces are no longer guaranteed and will be allotted on a first-come-first-serve basis. If a cohort fills - participants will need to reapply for a new cohort and incur an equivalent $100 fee.
- Deposits are non-refundable except in very specific situations where we determine that our training is not a good fit for you. This deposit will not be reimbursed unless cancellation is made within 24 hours of the deposit being submitted.
- Full tuition must be made 8 weeks prior to the in-person training, if payment is not made, you will forfeit your spot and your deposit will not be returned.
- Total registration fee must be paid 8-weeks prior to the training start date
- Please note that this requirement obviously doesn't apply to those who are joining training within 8 weeks of the start date
- Upon successful registration, full training portal access will be granted and you will be able to gain access to all reading and audio materials
- If registration and acceptance into the program is made within 8-weeks of training, the trainee will forgo the option to put down a deposit, and must register in full within the 7-day period post-acceptance.
- Trainees have an option for early-bird pricing if full-registration is made within 7 days of acceptance into the program and more than 8-weeks prior to the training start date. Following the 7-day mark, spaces are no longer guaranteed and will be allotted on a first-come-first-serve basis. If a cohort fills, participants will need to reapply for a new cohort and incur an equivalent $100 fee.
- **Payment plans are available, read more below
- Cancellations made within 8 weeks of the first day of training, will result in a penalty of 50% of the full training fee.
- Cancellations made 4 weeks or less prior to the first day of training, will result in a penalty of 100% of the full training fee.
- If cancellation is made within 24 hours of registration, a reimbursement of 100% of the registration fee will be made.
- Throughout the application process, trainees are given the opportunity to indicate their preferred training location, trainer, and date. For example: "Vancouver - September 11-15th - Dr. Ingrid Pacey."
- It is essential to note that the Application fee pertains to a single training cohort selection.
- If participants decide to switch cohorts after submitting their application, they will be required to reapply or face an associated fee of $100.
- If you have questions about the different trainers, please email firstname.lastname@example.org or join an TheraPsil Open House + Q&A, hosted every first Tuesday of the month.
- Once a deposit or registration fee has been received for a specific cohort, any subsequent request to transfer cohorts will incur a fee of $1000.
A minimum registration of six participants is required for a training cohort to move forward.
The program's effectiveness is typically assessed through participant feedback, evaluations, and post-training assessments. We continuously review and improve the program based on this feedback at weekly training meetings and monthly training committee meetings.
While we do not guarantee job placement, upon completion of training you will be added to TheraPsil’s Practitioner Directory for direct patient referrals. TheraPsil is also often approached by clinics seeking to hire graduates of our program.
We are committed to providing reasonable accommodations for participants with special needs or disabilities. Please contact our admissions team to discuss your specific requirements.
Since all our members are registered with a professional association or college, we rely and request that they follow the ethics codes and processes of the regulatory body they belong to.
The training program combines various formats, including lectures, peer-learning, guest expert speakers, art therapy, breathwork, and case studies to provide a comprehensive learning experience.